Nine Diagnostics – November 14, 2024
Nine Diagnostics is proud to announce its acceptance into the latest cohort of the Merck Digital Sciences Studio (MDS Studio), a digital accelerator designed to enable the next generation of technologies for drug discovery and development, including artificial intelligence and machine learning. MDS Studio was founded to offer support for early-stage biomedical startups providing strategic guidance, direct investment, and connection opportunities within Merck.
Nine Diagnostics, a medical diagnostics company focused on advancing functional precision medicine, was co-founded in 2024 by Freddy T. Nguyen, MD, PhD, Daniel Heller, PhD, and Mijin Kim, PhD. This opportunity marks a significant milestone in the company’s development and its pursuit of advancing precision medicine through an AI-enabled nanosensor platform technology and data analytics.
Nine Diagnostics has developed a proprietary platform designed to analyze biological samples at the molecular level, utilizing fluorescent nanosensors to identify changes indicative of disease states or therapeutic responses. This capability provides clinicians with real-time, granular biological data, enabling a more precise understanding of individual health profiles.
